Theratechnologies Inc T.TH

Official termination of distribution rights in Europe

[palinc2000]

BRIEF-Taimed Biologics Says It Has Terminated Theratechnologies' Exclusive Rights Of The Company's Product Trogarzo In Europe

Nov 1 (Reuters) - Taimed Biologics: 

* SAYS IT HAS TERMINATED THERATECHNOLOGIES’ EXCLUSIVE DISTRIBUTION RIGHTS OF THE COMPANY’S PRODUCT TROGARZO IN EUROPE 

* SAYS THERATECHNOLOGIES CONTINUES TO HOLD THE EXCUSIVE DISTRIBTUTION RIGHTS OF TROGARZO IN NORTH AMERICA Source text for Eikon: Further company coverage: (Reporting by Hong Kong newsroom) 

[Biobob]

I understand this formalizes an old news I guess but my first impression is... Why put this out for the algorithms to pickup and make more damage at this point in time.  What does this news bring to the table apsrt from a negative headline and additional frustration for shareholders.  It's a non event but still a negative headline to put out.  But maybe they have to because it

[qwerty22]

"Taimed Biologics Says" Nothing to do with them.  

[SPCEO1]

TH did not put out any press release about this today. Taimed announced it as they likely had to from a regulatory standpoint. But it shows up on Bloomberg as a headline for TH when you pull up a quote on THTX because TH is mentioned in Taimed's release about it. Despite that, the algo's do not seem to be paying attention to it. I would love to know what the final tally was on dollars TH

[Biobob]

That and the STRONG negociation position in P3 NASH/Partner.. we now are loonking at P2/3 and no partner like a year later.  No wonder they don't tell us anything about the cancer trial, maybe they learned it's better this way since they never make the deadline. As long as they succeed in the end.  At that point averything that was said on this board will vanish in oblivion and a

[qwerty22]

It's crazy. If they make a positive forward looking statements and it doesn't pan out they get kicked (NASH).  If they say nothing, wait for the picture to become clearer before saying something they get kicked (cancer). They (and us) are trying to deal with the uncertainty of biotech (it's a big part of the story). I don't know either are doing a good job of it